Q-omics provides the consensus-scored GAPDHP61 profile across patient tissues and cancer cell-line models. GAPDHP61 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GAPDHP61 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, GAPDHP61 RNA expression shows 14,327 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, KIRC, and ACC as cancer lineages where GAPDHP61 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP61 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP61 survival associations across molecular data types. GAPDHP61 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP61 RNA expression–survival associations across cancer types. High GAPDHP61 expression shows unfavorable associations in KICH, MESO, LIHC and ACC, but favorable associations in LUSC and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for GAPDHP61 RNA expression.
This table summarizes GAPDHP61 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP61. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP61 shows higher tumor expression in KIRC, COAD, LUAD, LUSC, HNSC and LIHC. The KIRC box plot shows higher GAPDHP61 RNA expression in tumor versus normal tissue (log2 FC = +0.352, t-test p < 0.001).
This table shows molecular features associated with GAPDHP61 in patient tissues and cancer cell lines. In patient samples, GAPDHP61 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
